3-Chloro-5-methyl-5H-benzo[b]pyridazino[4,3-e][1,4]oxazine

Catalog No. :
ACWRGL642
CAS No. :
27225-84-9
Molecular Formula :
C11H8ClN3O
Molecular Weight :
233.66

IUPAC Name:3-chloro-5-methyl-5H-benzo[b]pyridazino[4,3-e][1,4]oxazine

3-Chloro-5-methyl-5H-benzo[b]pyridazino[4,3-e][1,4]oxazine structure diagram
Pack SizePurityList PriceYour PriceGlobal StockUS StockQuantity
1g97%$271.00Login to see priceInquiryInquiry

Products of AiFChem are all designed for scientific research only. Under no circumstances do we provide products or services for animal or personal utilization.

Product Information

Product Name3-Chloro-5-methyl-5H-benzo[b]pyridazino[4,3-e][1,4]oxazine
IUPAC Name3-chloro-5-methyl-5H-benzo[b]pyridazino[4,3-e][1,4]oxazine
MDL No.MFCD00552945
Molecular FormulaC11H8ClN3O
Molecular Weight233.66
SMILESCN1C2=C(C=CC=C2)OC3=NN=C(Cl)C=C13
InChI KeyMLCQNZQXVSPVEE-UHFFFAOYSA-N
Synonym2-CHLORO-10-METHYL-3,4-DIAZAPHENOXAZINE;2-Chloro-10-methyl-3,4-diazaoxazine;5H-Pyridazino[3,4-b][1,4]benzoxazine, 3-chloro-5-Methyl-;3-chloro-5-methylpyridazino[3,4-b][1,4]benzoxazine;3-Chloro-5-methyl-5H-benzo[b]pyridazino[4,3-e][1,4]oxazine
CAS No.27225-84-9

Safety Data

Pictogram
Harmful or irritant
Signal Word
Achtung
Hazard Statement(s)
H302-H315-H319
Precautionary Statement(s)
P264-P270-P280-P301+P312+P330-P302+P352-P305+P351+P338-P332+P313-P337+P313-P362+P364-P501

Synthetic Route by SureRoute

1. ACWRGL642 Molecular Building Block Synthetic Route

Source: SureRouteAuthor: aifchem

  1. reactant_1 route compound structure diagram
    --
  2. Plus
  3. reactant_2 route compound structure diagram
    --
  4. Then
  5. ACWRGL642 route product structure diagram
    ACWRGL64227225-84-9
Inquiry

2. ACWRGL642 Molecular Building Block Synthetic Route

Source: SureRouteAuthor: aifchem

  1. ACVTAK269 route compound structure diagram
    ACVTAK269611-24-5 In Stock
  2. Plus
  3. ACSQID159 route compound structure diagram
    ACSQID1596082-66-2 In Stock
  4. Then
  5. ACWRGL642 route product structure diagram
    ACWRGL64227225-84-9
Inquiry

Comments (0)